Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
STRO

STRO - Sutro Biopharma Inc Stock Price, Fair Value and News

$15.75-0.87 (-5.23%)
Market Closed

50/100

STRO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

50/100

STRO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$15.86

Target 3M

$15.25

Target 6M

$15.46

STRO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

STRO Price Action

Last 7 days

-0.3%

Last 30 days

41.9%

Last 90 days

35.8%

Trailing 12 Months

-17.1%

STRO RSI Chart

STRO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

STRO Valuation

Market Cap

134.1M

Price/Earnings (Trailing)

-0.62

Price/Sales (Trailing)

1.27

EV/EBITDA

-0.38

Price/Free Cashflow

-0.6

STRO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$15.86

Target 3M

$15.25

Target 6M

$15.46

STRO Fundamentals

STRO Revenue

Revenue (TTM)

105.6M

Rev. Growth (Yr)

13.77%

Rev. Growth (Qtr)

-84.79%

STRO Earnings

Earnings (TTM)

-216.8M

Earnings Growth (Yr)

-16.54%

Earnings Growth (Qtr)

-394.45%

STRO Profitability

EBT Margin

-177.24%

Return on Equity

248.39%

Return on Assets

-103.39%

Free Cashflow Yield

-165.96%

STRO Investor Care

Shares Dilution (1Y)

3.25%

Diluted EPS (TTM)

-27.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202566.4M104.5M105.6M0
2024154.1M169.4M161.0M62.0M
202374.5M56.9M48.6M153.7M
202253.1M53.2M69.8M67.8M
202150.2M68.8M59.5M61.9M
202041.3M40.2M45.7M42.7M
201941.3M46.1M50.5M42.7M
201841.0M31.3M21.7M36.7M
201757.7M55.7M53.7M51.7M
201600059.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Sutro Biopharma Inc

STRO
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEsutrobio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES297

Sutro Biopharma Inc Frequently Asked Questions

STRO is the stock ticker symbol of Sutro Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sutro Biopharma Inc is 134.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check STRO's fair value in chart for subscribers.

The fair value guage provides a quick view whether STRO is over valued or under valued. Whether Sutro Biopharma Inc is cheap or expensive depends on the assumptions which impact Sutro Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STRO.

As of Wed Jan 28 2026, STRO's PE ratio (Price to Earnings) is -0.62 and Price to Sales (PS) ratio is 1.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STRO PE ratio will change depending on the future growth rate expectations of investors.